RxDoctor Payments DataLook up a doctor →

Carl Thornblade, MD

Allergy & Immunology · Missoula, MTNPI 1073605200

Payments from drug & device makers

$1,364,914in general payments, 2019–2025

Across 740 payments — averaging $1844.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$254K
  • AstraZeneca$243K
  • Teva Pharmaceuticals USA, Inc.$162K
  • Hikma Pharmaceuticals USA$131K
  • LEO Pharma AS$126K
  • Regeneron$111K
  • plus $338K from 37 others
$1,348in research payments, 2019–2025

Across 9 payments — averaging $149.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1K
  • Teva Pharmaceuticals USA, Inc.$173

What the payments were for

  • Consulting fees$5,15920%
  • Speaking & faculty fees$6,56725%
  • Travel & lodging$3,96815%
  • Food & beverage$10,19539%
  • Education$1020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$425,202
Medicare patients
205
Services billed
16,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab36$131,532
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$46,566
Breo ElliptaFluticasone/Vilanterol16$13,166
Cromolyn Sodium12$7,606
DuleraMometasone/Formoterol16$6,984
Advair HfaFluticasone Propion/Salmeterol11$4,968
Arnuity ElliptaFluticasone Furoate13$4,264
Epinephrine12$2,174
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,651
Albuterol Sulfate HfaAlbuterol Sulfate40$1,169
Montelukast Sodium36$548
Ipratropium Bromide18$465
Fluticasone Propionate13$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$75,328$63,99676 claims
Cycle Pharmaceuticals IncCromolyn Sodium$51$7,60612 claims
Hikma Pharmaceuticals USAEpinephrine$130,548$2,17412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →